BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37266806)

  • 1. ASO Author Reflections: Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Ann Surg Oncol; 2023 Sep; 30(9):5895-5896. PubMed ID: 37266806
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Prediction of the Response to Neoadjuvant Therapy by Patients with Esophageal Squamous Cell Carcinoma.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Ann Surg Oncol; 2023 Apr; 30(4):2186-2187. PubMed ID: 36538253
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on "Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study".
    Gronnier C
    Ann Surg Oncol; 2024 May; 31(5):2815-2817. PubMed ID: 38355781
    [No Abstract]   [Full Text] [Related]  

  • 4. ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Okamura A; Matsuda S; Kawakubo H; Mine S; Takeuchi H; Kitagawa Y; Watanabe M
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):795-796. PubMed ID: 32591950
    [No Abstract]   [Full Text] [Related]  

  • 5. ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Huang X; Tan L
    Ann Surg Oncol; 2024 Feb; 31(2):899-900. PubMed ID: 38006528
    [No Abstract]   [Full Text] [Related]  

  • 6. ASO Author Reflections: Response to Neoadjuvant Chemotherapy Strengthens the Prognostic Impact of Pathological Stage for Esophageal Squamous Cell Carcinoma.
    Matsuda S; Kawakubo H; Okamura A; Takahashi K; Toihata T; Takemura R; Mayanagi S; Takeuchi H; Watanabe M; Kitagawa Y
    Ann Surg Oncol; 2021 Dec; 28(13):8448-8449. PubMed ID: 34143335
    [No Abstract]   [Full Text] [Related]  

  • 7. ASO Author Reflections: A Novel, Sensitive, and Effective Index in Predicting Therapeutic Response of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
    Feng J; Wang L; Yang X; Chen Q; Cheng X
    Ann Surg Oncol; 2024 Jan; 31(1):241-242. PubMed ID: 37838649
    [No Abstract]   [Full Text] [Related]  

  • 8. ASO Author Reflections: Preservation of the Thoracic Duct is Feasible for Esophageal Squamous Cell Carcinoma Patients Treated with Esophagectomy After Neoadjuvant Chemoradiotherapy.
    Oshikiri T; Numasaki H; Oguma J; Toh Y; Watanabe M; Muto M; Kakeji Y; Doki Y
    Ann Surg Oncol; 2023 May; 30(5):2699-2700. PubMed ID: 36629993
    [No Abstract]   [Full Text] [Related]  

  • 9. ASO Author Reflections: Biomarkers for Neoadjuvant Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma.
    Okumura H; Noda M; Natsugoe S
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):715-716. PubMed ID: 30288651
    [No Abstract]   [Full Text] [Related]  

  • 10. ASO Author Reflections: Comparison of Aggressive Planned Salvage Surgery versus Neoadjuvant Chemoradiotherapy Plus Surgery for Borderline Resectable T4 Squamous Cell Carcinoma.
    Shiraishi O
    Ann Surg Oncol; 2021 Oct; 28(11):6376-6377. PubMed ID: 33830358
    [No Abstract]   [Full Text] [Related]  

  • 11. Definitive chemoradiotherapy has comparable survival outcomes to esophagectomy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: real-world data.
    Sawada K; Kotani D; Yukami H; Mishima S; Fujiwara H; Kadota T; Nakajo K; Yoda Y; Nakamura M; Hojo H; Yano T; Fujita T; Kojima T
    Int J Clin Oncol; 2022 Aug; 27(8):1279-1288. PubMed ID: 35779118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASO Author Reflections: Treatment Strategies for Locally Advanced Borderline Resectable Esophageal Squamous Cell Carcinoma.
    Hong Y
    Ann Surg Oncol; 2024 Feb; 31(2):896. PubMed ID: 37962739
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from A Japanese Nationwide Study.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Ann Surg Oncol; 2023 Sep; 30(9):5885-5894. PubMed ID: 37264286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASO Author Reflections: Timing of Oesophagectomy After Neoadjuvant Chemoradiotherapy for Locally Advanced Oesophageal Cancer.
    Xiao X; Cheng C; Cheng L; Yuan Y
    Ann Surg Oncol; 2023 Feb; 30(2):897-898. PubMed ID: 36322273
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Esophagectomy Versus Nonsurgical Treatment for Resectable Esophageal Cancer.
    Ohkura Y
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):703-704. PubMed ID: 30251022
    [No Abstract]   [Full Text] [Related]  

  • 16. ASO Author Reflections: How Should We Approach Borderline Resectable Esophageal Squamous Cell Carcinoma?
    Suzuki T; Okamura A; Watanabe M; Chin K
    Ann Surg Oncol; 2020 May; 27(5):1518-1519. PubMed ID: 32108921
    [No Abstract]   [Full Text] [Related]  

  • 17. To radiate or not to radiate: that is the question?-a commentary on "Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial".
    Chandra R; Reznik SI
    Chin Clin Oncol; 2023 Dec; 12(6):60. PubMed ID: 37731309
    [No Abstract]   [Full Text] [Related]  

  • 18. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
    Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
    Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASO Author Reflections: Association Between Preoperative Coagulation Status and Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell Carcinoma After Neoadjuvant Treatment.
    Sugiyama F; Kanda M; Kodera Y
    Ann Surg Oncol; 2024 May; 31(5):3473-3474. PubMed ID: 38261127
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: Esophagectomy or Chemoradiotherapy, That is the Question: Additional Treatment Following Noncurative Endoscopic Resection for Esophageal Squamous Cell Carcinoma.
    Kanie Y; Okamura A; Asari T; Ishiyama A; Yoshio T; Tsuchida T; Chin K; Watanabe M
    Ann Surg Oncol; 2021 Dec; 28(13):8436-8437. PubMed ID: 34115253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.